HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Altimmune (NASDAQ:ALT) and maintained a $15 price target on the stock.
December 01, 2023 | 7:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating on Altimmune with a $15 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and the maintenance of a $15 price target by a reputable analyst could lead to increased investor confidence in Altimmune, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100